文献速递免疫规划传染病防控与疫情报告卫生政策与健康促进

登革热疫苗:保护相关物在疫苗安全性与风险评估中的作用

Dengue vaccines: The role of a correlate of protection in evaluating vaccine safety and risk.
PubMed 文献 · Vaccine · 2026-07-22

登革热疫苗开发因缺乏经验证的保护相关物(CoP)而依赖昂贵的三期试验,难以评估未感染者的分血清型安全性与有效性。2024年3月专家会议提出以型特异性中和抗体作为最有希望的生物标志物,并强调需统一检测方法与验证研究以加速疫苗上市。

要点

  • 型特异性中和抗体是登革热未感染者最有希望的保护相关物候选。
  • 缺乏经验证CoP导致疫苗开发依赖大型昂贵且统计效能不足的三期试验。
  • 专家强调需统一检测方法并利用临床试验样本开展CoP验证研究。

核心结论

  • 专家共识认为型特异性中和抗体是登革热未感染者最有希望的保护相关物,可加速疫苗开发与上市。

研究设计与样本

  • 2024年3月14-15日在波多黎各圣胡安召开的专家会议,汇集学术界、政府、美国监管机构与公共卫生组织专家。

主要发现

  • 缺乏经验证CoP使疫苗开发依赖大型、昂贵、复杂的三期现场效力试验,且对未感染者的分血清型效力与安全性评估常统计效能不足。
  • 经验证CoP可帮助开发者选择候选疫苗、支持基于较短效力终点试验的上市许可,并利用免疫原性数据桥接其他人群。
  • 会议识别了CoP验证的关键障碍,包括检测方法缺乏标准化和监管共识有限。

关键数值与推荐

  • 专家同意针对每个血清型独特表位的中和抗体(即型特异性抗体)是登革热未感染者最有希望的生物标志物。
  • 强调需统一检测方法并使用临床试验样本开展验证研究。
  • 讨论了人类挑战试验和非人灵长类模型等替代试验模式在三期效力数据不完整时补充监管提交的作用。

临床怎么用

  • 疫苗开发者可优先考虑型特异性中和抗体作为CoP候选,并推动检测标准化与验证研究。
  • 监管机构与公共卫生组织可参考会议框架协调科学、监管与产业努力以加速登革热疫苗上市与实施。

局限性

  • 本文为专家会议共识,未报告具体验证数据或样本量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Dengue remains a significant global health challenge, with incidence rising and over half the world's population at risk. Vaccines could play an important role in controlling dengue, but without a validated correlate of protection (CoP), vaccine development relies on large, costly, and complex phase 3 field efficacy trials that are often underpowered for evaluating efficacy and safety by individual DENV serotypes in individuals who have never been infected with a dengue virus (i.e., DENV-naïve individuals). A validated CoP would help developers make informed decisions about the best vaccine candidates for testing in costly phase 3 field trials. A CoP might enable licensure of dengue vaccines based on efficacy endpoint trials of shorter duration and use of immunogenicity data to bridge efficacy data to other populations, which could accelerate the pathway from vaccine trials to operational dengue vaccination programs. Recognizing the urgent need for vaccine development and licensure, a group of experts in dengue vaccinology convened in San Juan, Puerto Rico, from March 14-15, 2024, to define a research agenda for establishing a CoP. The meeting brought together experts from academia, government, U.S. regulatory agencies, and public health organizations who identified key barriers to CoP validation, discussed lack of assay standardization and limited regulatory consensus, and identified the most promising CoP candidates. Experts agreed that neutralizing antibodies to unique epitopes on each serotype (i.e., type-specific antibodies) are the most promising biomarker for DENV-naïve individuals (the most challenging subgroup for establishing safety and efficacy) and emphasized the need for harmonized assays and validation studies using clinical trial samples. The group also discussed the role of alternative trial modalities, such as human challenge studies and nonhuman primate models, in supplementing regulatory submissions where phase 3 efficacy data may be incomplete. This article outlines the key research priorities identified at the meeting and provides a framework for advancing CoP validation to accelerate dengue vaccine development, licensure, and implementation. By aligning scientific, regulatory, and industry efforts around these priorities, the field can move more quickly toward broad access to safe and effective dengue vaccines.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Wong JM, Acevedo PK, Whitehead S, et al. Dengue vaccines: The role of a correlate of protection in evaluating vaccine safety and risk. Vaccine. 2026. PMID: 42486049. doi:10.1016/j.vaccine.2026.128599

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。